Yang, Y., Fan, Z., He, Y., Ouyang, T. (2026). Updated overall survival results from a randomized phase III trial of non–cross-resistant adjuvant chemotherapy plus endocrine therapy versus endocrine therapy alone in HR+/HER2−/lymph node–positive breast cancer with residual disease following neoadjuvant chemotherapy (NCT01019616).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.506